Opportunity Information: Apply for RFA CA 22 017
The Small Business Transition Grant for Early Career Scientists (R42, Clinical Trial Not Allowed), funding opportunity number RFA-CA-22-017, is a National Institutes of Health (NIH) grant designed to help early-career academic researchers make a practical jump from the university setting into entrepreneurship. The program is built around a common reality in biomedical innovation: universities are strong at generating discoveries, while small businesses are often better positioned to turn those discoveries into real-world products. NIH recognizes that the handoff between these two worlds can be difficult, so this opportunity aims to make that transition smoother and more intentional.
At its core, the FOA targets two problems that often slow down or derail academic-to-startup technology transfer. The first is the people problem: promising technologies frequently stall because the right team is not yet in place, particularly a leader who understands both the science and the requirements of building a product in a business environment. The second is the early funding problem: even strong inventions may be too early for private investment, and standard academic grants may not be structured to support the product-focused development steps needed to make a technology commercially viable. This announcement tries to address both at the same time by treating entrepreneurial mentoring and early-stage product development as equally important goals, rather than treating business training as a minor add-on.
The intended applicants are U.S. small businesses, aligning with NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) pathways, and the mechanism listed is an R42, which is typically associated with STTR-style projects. The emphasis is on moving a technology out of an academic laboratory and into a small business context, while actively supporting an early-career scientist who is stepping into an entrepreneurial role. In other words, it is not only about advancing a piece of technology; it is also about developing the scientist into someone who can lead or meaningfully contribute to commercialization efforts.
This opportunity is explicitly not for clinical trials, as indicated by the "Clinical Trial Not Allowed" designation. That generally means the supported work should focus on preclinical development, prototyping, validation, engineering, feasibility studies, or other product development activities that do not involve assigning human participants to interventions to evaluate health-related outcomes. Applicants would be expected to shape their aims accordingly, keeping the project on the technology development and commercialization preparation side rather than human clinical testing.
Eligibility restrictions are also clear and fairly strict regarding foreign participation. Non-U.S. entities (foreign institutions) cannot apply, and non-U.S. components of U.S. organizations are not eligible to apply. However, the FOA notes that "foreign components" as defined in the NIH Grants Policy Statement may be allowed, which typically refers to limited, well-justified parts of the project being performed outside the U.S. under specific NIH rules and approvals. In practice, that means the main applicant organization must be a U.S. small business, and most of the work should remain domestically based unless there is a strong justification that meets NIH policy definitions.
The opportunity sits within NIH's broader mission to support health-related innovation, and it is categorized under education and health-related funding activities with CFDA numbers 93.279, 93.286, and 93.394. The listing shows the original closing date as 2022-08-22, with a creation date of 2022-03-21, indicating it was a time-bound announcement. Even if the window has passed, the structure is still useful as a model for how NIH designs programs that blend commercialization training with technical development funding.
Overall, this FOA is best understood as a bridge: it helps an early-career academic scientist move toward entrepreneurship while pushing an academic invention toward a product pathway inside a U.S. small business. It is meant to strengthen the leadership pipeline for scientist-entrepreneurs and to reduce the early technical and organizational friction that so often prevents good laboratory innovations from becoming practical tools, diagnostics, devices, or other technologies that can benefit the public.Apply for RFA CA 22 017
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279, 93.286, 93.394.
- This funding opportunity was created on 2022-03-21.
- Applicants must submit their applications by 2022-08-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the Small Business Transition Grant for Early Career Scientists (R42, Clinical Trial Not Allowed)?
It is a National Institutes of Health (NIH) funding opportunity designed to help early-career academic researchers transition from a university environment into entrepreneurship by moving an academic discovery into a U.S. small business setting. The program supports both (1) early-stage, product-oriented technology development and (2) the intentional development of an early-career scientist into an entrepreneurial leader or key commercialization contributor.
What is the funding opportunity number for this FOA?
The funding opportunity number is RFA-CA-22-017.
What grant mechanism does this opportunity use?
The mechanism is an R42, which is typically associated with Small Business Technology Transfer (STTR)-style projects and emphasizes moving technology between a research institution environment and a small business context.
Who is the intended applicant for this grant?
The intended applicant is a U.S. small business, consistent with NIH SBIR/STTR pathways. The program focus is on transitioning an academic innovation into a small business environment while supporting an early-career scientist in an entrepreneurial role.
What is the main purpose of this grant opportunity?
The FOA is meant to serve as a bridge between academic discovery and real-world product development by supporting (a) technology transfer from a university lab to a small business and (b) the development of a capable team and leadership, especially an early-career scientist who can operate effectively in a business and commercialization setting.
What problems is the FOA trying to solve?
The FOA targets two common barriers in academic-to-startup translation: (1) the "people problem," where a promising technology stalls because the right product-minded team or leader is not yet in place, and (2) the "early funding problem," where an invention is too early for private investment and traditional academic funding may not fit product-focused development needs.
How does this program support early-career scientists specifically?
Beyond advancing the technology itself, the program treats entrepreneurial mentoring and early-stage product development as co-equal goals. It is designed to help an early-career academic scientist make a practical shift into entrepreneurship and build the skills and experience needed to lead or significantly contribute to commercialization activities.
Is this grant meant for universities or for startups?
Based on the eligibility description provided, the main applicant is expected to be a U.S. small business. The core emphasis is moving a technology out of an academic laboratory into a small business context, rather than funding purely university-based research.
Are clinical trials allowed under this FOA?
No. The FOA is designated "Clinical Trial Not Allowed," meaning the supported work should not involve assigning human participants to interventions to evaluate health-related outcomes.
What kinds of activities are appropriate if clinical trials are not allowed?
The project should focus on preclinical development and product-oriented work such as prototyping, validation, engineering, feasibility studies, and other technology development activities that prepare an innovation for commercialization without conducting human clinical testing.
What types of technologies or products is this grant trying to advance?
The FOA is positioned as a bridge to move biomedical innovations toward practical products that can benefit the public. Examples described at a high level include tools, diagnostics, devices, or other health-related technologies that originate in academic research and need product-focused development within a small business.
Does the FOA treat business training as optional?
No. The description emphasizes that entrepreneurial mentoring and early-stage product development are treated as equally important goals, rather than treating business training as a minor add-on.
Can a non-U.S. organization apply?
No. Non-U.S. entities (foreign institutions) cannot apply, and non-U.S. components of U.S. organizations are not eligible to apply.
Are any foreign activities allowed at all?
Possibly, in limited circumstances. The FOA notes that "foreign components" as defined in the NIH Grants Policy Statement may be allowed. In practice, this suggests the main applicant must be a U.S. small business and most work should be domestically based, with any foreign component needing strong justification and alignment with NIH policy definitions and approvals.
What does it mean that the opportunity aligns with NIH SBIR and STTR pathways?
It means the opportunity is structured around NIH's small business innovation frameworks and is intended for eligible U.S. small businesses. The R42 mechanism is commonly associated with STTR-style technology transfer and development efforts.
What is NIH trying to accomplish with this program in the bigger picture?
The program supports NIH's health-related innovation mission by strengthening the pipeline of scientist-entrepreneurs and reducing early technical and organizational friction that often prevents laboratory discoveries from becoming practical products.
What are the CFDA numbers associated with this opportunity?
The CFDA numbers listed are 93.279, 93.286, and 93.394.
When was this FOA created, and what was the original closing date?
The listing shows a creation date of 2022-03-21 and an original closing date of 2022-08-22, indicating it was a time-bound announcement.
If the closing date has passed, is the FOA still useful?
Even if the application window has passed, the structure can still be useful as a model for how NIH designs programs that combine commercialization training, entrepreneurial mentoring, and product development funding to support academic-to-small-business transitions.
What is the simplest way to summarize this opportunity?
It is a bridge program: it helps an early-career academic scientist move toward entrepreneurship while pushing an academic invention into a product development pathway inside a U.S. small business, without supporting clinical trials.
Browse more opportunities from the same category: Education, Health
Next opportunity: GM-21-x03: Environmental Justice Technical Workshops for the Gulf of Mexico Region
Previous opportunity: Bureau of Land Management ORWA Cultural and Paleontological Resources Management
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 22 017
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 22 017) also looked into and applied for these:
| Funding Opportunity |
|---|
| Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) Apply for PAR 22 126 Funding Number: PAR 22 126 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Focused Technology Research and Development (R01 Clinical Trial Not Allowed) Apply for PAR 22 127 Funding Number: PAR 22 127 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) Apply for RFA CA 22 023 Funding Number: RFA CA 22 023 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) Apply for RFA CA 22 024 Funding Number: RFA CA 22 024 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) Apply for RFA CA 22 022 Funding Number: RFA CA 22 022 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) Apply for RFA CA 22 021 Funding Number: RFA CA 22 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24 Clinical Trial Not Allowed) Apply for RFA CA 22 013 Funding Number: RFA CA 22 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Patient Derived Xenograft (PDX) Development and Trial Centers (PDTCs) Network (U54 Clinical Trial Not Allowed) Apply for RFA CA 22 012 Funding Number: RFA CA 22 012 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional) Apply for RFA DA 23 021 Funding Number: RFA DA 23 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed) Apply for RFA AI 22 025 Funding Number: RFA AI 22 025 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional) Apply for PAR 22 145 Funding Number: PAR 22 145 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Pediatric Immunotherapy Network (PIN) (U01 Clinical Trial Optional) Apply for RFA CA 22 016 Funding Number: RFA CA 22 016 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) Apply for RFA CA 22 020 Funding Number: RFA CA 22 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: $475,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) Apply for RFA CA 22 025 Funding Number: RFA CA 22 025 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,000,000 |
| Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required) Apply for RFA DA 23 002 Funding Number: RFA DA 23 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) Apply for PAR 22 161 Funding Number: PAR 22 161 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research Projects in Physical Sciences-Oncology (U01 Clinical Trial Optional) Apply for PAR 22 147 Funding Number: PAR 22 147 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) Apply for PAR 22 136 Funding Number: PAR 22 136 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional) Apply for PAR 22 131 Funding Number: PAR 22 131 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Interaction Targeted Epidemiology: Viral Suppression (LITE-VS) (UG3/UH3 Clinical Trial Optional) Apply for RFA AI 22 024 Funding Number: RFA AI 22 024 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 22 017", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.